Studies in PC cell lines and orthotopic xenografts revealed that targeting IL-1 signaling is a promising strategy and two phase 1 studies evaluated safety of the combination of IL-1 receptor inhibitor Anakinra in association with chemotherapy in advanced PC patients (NCT02021422) (NCT02550327) [167,168]. This evidence concerns the gene IL1A and pachyonychia congenita.